Intellia Therapeutics, Inc (NTLA)

Price$13.54

Value ScoreD

Growth ScoreC

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)42.69%

Price vs S&P 500 (4W)-3.89%

VGM Score50.36

Market Capitalization$1.89B

All Metrics

Book Value / Share (Quarterly)$5.16

P/TBV (Annual)2.25x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)9.09%

Cash Flow / Share (Quarterly)$-3.02

Price vs S&P 500 (YTD)42.45%

Net Profit Margin (TTM)-597.04%

EPS (TTM)$-3.53

10-Day Avg Trading Volume5.11M

EPS Excl Extra (TTM)$-3.53

Revenue Growth (5Y)3.14%

EPS (Annual)$-3.81

ROI (Annual)-61.47%

Net Profit Margin (5Y Avg)-910.70%

Cash / Share (Quarterly)$3.12

Revenue Growth QoQ (YoY)-9.50%

ROA (Last FY)-49.01%

Revenue Growth TTM (YoY)45.04%

EBITD / Share (TTM)$-3.67

ROE (5Y Avg)-46.19%

Operating Margin (TTM)-636.56%

Cash Flow / Share (Annual)$-3.40

P/B Ratio3.05x

P/B Ratio (Quarterly)2.44x

Net Income / Employee (Annual)$-1,094,700

EV / Revenue (TTM)26.59x

Net Interest Coverage (TTM)-185.69x

ROA (TTM)-46.08%

EPS Incl Extra (Annual)$-3.81

Current Ratio (Annual)5.08x

Quick Ratio (Quarterly)5.04x

3-Month Avg Trading Volume5.19M

52-Week Price Return78.63%

Revenue / Employee (TTM)$175,300

Tangible BV / Share (Quarterly)$11.64

P/S Ratio (Annual)27.96x

Asset Turnover (Annual)0.08x

52-Week High$28.25

Operating Margin (5Y Avg)-936.95%

EPS Excl Extra (Annual)$-3.81

CapEx CAGR (5Y)-20.65%

Tangible BV CAGR (5Y)32.67%

26-Week Price Return50.61%

Quick Ratio (Annual)4.42x

13-Week Price Return2.97%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.10x

Enterprise Value$1.76B

Revenue / Share Growth (5Y)-9.63%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)-6.23%

Revenue / Employee (Annual)$179,500

Pretax Margin (Annual)-609.85%

Cash / Share (Annual)$3.87

3-Month Return Std Dev75.22%

Net Income / Employee (TTM)$-1,046,700

ROE (Last FY)-61.47%

Net Interest Coverage (Annual)-17.53x

EPS Basic Excl Extra (Annual)$-3.81

P/FCF (TTM)33.55x

Receivables Turnover (TTM)6.73x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.53

Receivables Turnover (Annual)7.53x

ROI (TTM)-57.27%

P/S Ratio (TTM)28.62x

Pretax Margin (5Y Avg)-910.70%

Revenue / Share (Annual)$0.62

Tangible BV / Share (Annual)$14.19

Price vs S&P 500 (52W)54.26%

Year-to-Date Return50.61%

5-Day Price Return-1.38%

EPS Normalized (Annual)$-3.81

ROA (5Y Avg)-36.29%

Net Profit Margin (Annual)-609.85%

Month-to-Date Return-3.77%

Cash Flow / Share (TTM)$-5.25

EBITD / Share (Annual)$-3.98

Operating Margin (Annual)-651.67%

ROI (5Y Avg)-46.19%

EPS Basic Excl Extra (TTM)$-3.53

P/TBV (Quarterly)2.68x

P/B Ratio (Annual)1.55x

Pretax Margin (TTM)-597.04%

Book Value / Share (Annual)$5.77

Price vs S&P 500 (13W)-5.29%

Beta1.82x

P/FCF (Annual)63.19x

Revenue / Share (TTM)$0.56

ROE (TTM)-57.27%

52-Week Low$7.31

vGradeD

gGradeC

mGradeB

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.81est. -0.93

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.60

3.70

Industry Peers — In Vitro Diagnostics(18)

Symbol	Value Score	Growth Score	Momentum Score	Price
NTLAIntellia Therapeutics, Inc	D	C	B	$13.54
IDXXIdexx Laboratories Inc	D	B	C	$562.16
LNTHLantheus Holdings, Inc	C	B	B	$100.98
NNNNAnbio Biotechnology Class A Ordinary Shares	F	B	B	$22.99
CLDXCelldex Therapeutics, Inc	F	F	C	$28.62
NEOGNeogen Corp	C	C	B	$8.90
QDELQuidelOrtho Corporation Common Stock	C	C	D	$14.33
ACHVAchieve Life Sciences, Inc.	F	F	B	$5.13
MYGNMyriad Genetics Inc	C	C	C	$4.57
TKNOAlpha Teknova, Inc. Common Stock	C	C	B	$4.56
IMDXInsight Molecular Diagnostics Inc. Common Stock	F	D	C	$5.24

About

Intellia Therapeutics develops CRISPR-based gene therapies to treat genetically defined diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, and sickle cell disease. The company employs both in vivo and ex vivo therapeutic approaches across its pipeline. Strategic partnerships with Regeneron and Novartis provide clinical and commercial validation for its gene-editing platform.